dupilumab
regeneron,sanofi
['dupixent', 'derm', 'prurigo nodularis', 'dupilumab']
dupixent (dupilumab) late-breaking phase 3 data at the eadv 2022 congress showed ... ... significant improvements in signs and symptoms of prurigo nodularis. ... approved indications for dupixent such as asthma, atopic dermatitis, ...
#TheAsthmaCures https://t.co/vRkYeArZWg helping those with chronic #asthma https://t.co/7SMiyxzFdG resolving https://t.co/nIlzNga34W https://t.co/T67YXQ3eBZ